| Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa KA Khan, RS Kerbel Nature Reviews Clinical Oncology 15 (5), 310-324, 2018 | 531 | 2018 |
| The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression EJ Haining, J Yang, RL Bailey, K Khan, R Collier, S Tsai, SP Watson, ... Journal of Biological Chemistry 287 (47), 39753-39765, 2012 | 189 | 2012 |
| The emerging role of tetraspanin microdomains on endothelial cells RL Bailey, JM Herbert, K Khan, VL Heath, R Bicknell, MG Tomlinson Biochemical Society Transactions 39 (6), 1667-1673, 2011 | 87 | 2011 |
| Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface KA Khan, AJ Naylor, A Khan, PJ Noy, M Mambretti, P Lodhia, J Athwal, ... Oncogene 36 (44), 6097-6108, 2017 | 78 | 2017 |
| C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation KA Khan, JL McMurray, F Mohammed, R Bicknell The FEBS journal 286 (17), 3299-3332, 2019 | 72 | 2019 |
| Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth PJ Noy, P Lodhia, K Khan, X Zhuang, DG Ward, AR Verissimo, A Bacon, ... Oncogene 34 (47), 5821-5831, 2015 | 67 | 2015 |
| Pre-and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro-or macro-metastatic disease FTH Wu, P Xu, A Chow, S Man, J Krüger, KA Khan, M Paez-Ribes, ... British journal of cancer 120 (2), 196-206, 2019 | 40 | 2019 |
| Sprouting angiogenesis is regulated by shedding of the C‐type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid‐like 2 protein (RHBDL2) PJ Noy, RK Swain, K Khan, P Lodhia, R Bicknell The FASEB Journal 30 (6), 2311-2323, 2016 | 38 | 2016 |
| Tumors resurrect an embryonic vascular program to escape immunity EJM Huijbers, KA Khan, RS Kerbel, AW Griffioen Science immunology 7 (67), eabm6388, 2022 | 36 | 2022 |
| Anti-angiogenic alternatives to VEGF blockade KA Khan, R Bicknell Clinical & experimental metastasis 33, 197-210, 2016 | 35 | 2016 |
| A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding J Zuo, CR Willcox, F Mohammed, M Davey, S Hunter, K Khan, A Antoun, ... Science signaling 10 (481), eaai8904, 2017 | 34 | 2017 |
| Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer KA Khan, JL Ponce de Léon, M Benguigui, P Xu, A Chow, W Cruz-Muñoz, ... NPJ Breast Cancer 6 (1), 29, 2020 | 31 | 2020 |
| Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer KA Khan, FTH Wu, W Cruz‐Munoz, RS Kerbel EMBO Molecular Medicine 13 (7), e08253, 2021 | 29 | 2021 |
| Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials HY Kuo, KA Khan, RS Kerbel Nature Reviews Clinical Oncology, 1-15, 2024 | 9 | 2024 |
| A CD276 antibody guided missile with one warhead and two targets: the tumor and its vasculature KA Khan, RS Kerbel Cancer cell 31 (4), 469-471, 2017 | 9 | 2017 |
| A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis KA Khan, RS Kerbel EMBO Molecular Medicine 12 (6), e12355, 2020 | 7 | 2020 |
| Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis R Bicknell, P Noy, KA Khan US Patent 10,808,031, 2020 | 1 | 2020 |
| Investigating the extracellular interactions of the tumour endothelial marker CLEC14A KA Khan University of Birmingham, 2016 | 1 | 2016 |
| Inhibitors of the Interaction Between CLEC14A and Multimerin-2 for Inhibition of Angiogenesis R Bicknell, P Noy, KA Khan US Patent App. 16/992,497, 2021 | | 2021 |
| Inhibitors R Bicknell, KA Khan US Patent App. 16/320,522, 2019 | | 2019 |
Robert S. KerbelSunnybrook Research Institute在 sri.utoronto.ca 的电子邮件经过验证
